Life-Threatening Effects of Antipsychotic Drugs:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Saint Louis
Elsevier Science
2016
|
| Online-Zugang: | FAW01 FLA01 Inhaltsverzeichnis |
| Beschreibung: | Description based on publisher supplied metadata and other sources |
| Beschreibung: | 1 online resource (396 pages) |
| ISBN: | 9780128033906 9780128033760 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043895638 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 161123s2016 |||| o||u| ||||||eng d | ||
| 020 | |a 9780128033906 |9 978-0-12-803390-6 | ||
| 020 | |a 9780128033760 |c Print |9 978-0-12-803376-0 | ||
| 035 | |a (ZDB-30-PQE)EBC4648365 | ||
| 035 | |a (ZDB-89-EBL)EBL4648365 | ||
| 035 | |a (ZDB-38-EBR)ebr11249443 | ||
| 035 | |a (OCoLC)957318289 | ||
| 035 | |a (DE-599)BVBBV043895638 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 | ||
| 082 | 1 | |a 615.7882 |2 23 | |
| 100 | 1 | |a Manu, Peter |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Life-Threatening Effects of Antipsychotic Drugs |
| 264 | 1 | |a Saint Louis |b Elsevier Science |c 2016 | |
| 264 | 4 | |c © 2016 | |
| 300 | |a 1 online resource (396 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on publisher supplied metadata and other sources | ||
| 700 | 1 | |a Flanagan, Robert J. |e Sonstige |4 oth | |
| 700 | 1 | |a Ronaldson, Kathlyn J. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Manu, Peter |t Life-Threatening Effects of Antipsychotic Drugs |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029305019&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 912 | |a ZDB-30-PQE |a ZDB-33-ESD |a ZDB-33-EBS | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029305019 | ||
| 966 | e | |u http://www.sciencedirect.com/science/book/9780128033760 |l FAW01 |p ZDB-33-ESD |q FAW_PDA_ESD |x Verlag |3 Volltext | |
| 966 | e | |u http://www.sciencedirect.com/science/book/9780128033760 |l FLA01 |p ZDB-33-ESD |q FLA_PDA_ESD |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176795800436736 |
|---|---|
| adam_text | Titel: Life-threatening effects of antipsychotic drugs
Autor: Manu, Peter
Jahr: 2016
Contents
List of Contributors xiii
Foreword XV
Preface xvii
Acknowledgments xix
Symbols and Conventions xxi
Part 1
Cardiovascular Adverse Effects of Antipsychotic Drugs
1. Sudden Cardiac Death and Ventricular Arrhythmias 3
Peter Manu, Anca Dan and Gheorghe-Andrei Dan
1.1 Epidemiology 3
1.2 Pathobiology 10
1.2.1 Determinants of APD 10
1.2.2 Amplification of Myocardial Dispersion
of Repolarization 13
1.2.3 The Initiation and Perpetuation of TdP 14
1.2.4 Drug-Induced Prolongation of QT interval
and TdP 15
1.2.5 Antipsychotic-lnduced QTc Prolongation 16
1.3 Clinical and Laboratory Features 20
1.4 Prevention and Management 21
References 22
2. Myocarditis and Cardiomyopathy
Kathlyn J. Ronaldson
2.1 Definitions 27
2.2 Epidemiology 28
2.2.1 Causality 28
2.2.2 Prevalence and Incidence 30
2.2.3 Risk Factors 32
2.3 Genetic Vulnerability 34
2.4 Pathobiology 35
2.4.1 Myocarditis 35
2.4.2 Cardiomyopathy 36
v
vi Contents
2.5 Clinical and Laboratory Features 38
2.5.1 Myocarditis 38
2.5.2 Cardiomyopathy 42
2.6 Differential Diagnosis 42
2.6.1 Myocarditis 42
2.6.2 Cardiomyopathy 45
2.7 Complications and Significant Sequelae 46
2.8 Risk Stratification for Death or Permanent Disability 47
2.9 Management 48
2.9.1 Myocarditis 48
2.9.2 Cardiomyopathy 49
2.10 Prevention 50
2.10.1 Myocarditis 50
2.10.2 Cardiomyopathy 52
Acknowledgment 52
References 52
3. Pulmonary Embolism
Peter Manu, Christopher Hohman, James F. Barrecchia
and Matisyahu Shulman
3.1 Epidemiology 59
3.2 Pathobiology 62
3.2.1 Venous Stasis as a Consequence of Obesity
and Physical Inactivity 63
3.2.2 Hypercoagulability 64
3.2.3 Endothelial Injury 65
3.3 Clinical and Laboratory Features 65
3.3.1 Clinical Presentation 65
3.3.2 Diagnosing Pulmonary Embolism in Psychiatric
Patients 68
3.4 Prevention and Management 71
3.4.1 Intravenous Unfractionated Heparin and Oral
Vitamin K Antagonists 71
3.4.2 Subcutaneous Low Molecular Weight Heparin
and Oral Vitamin K Antagonists 71
3.4.3 Oral Factor Xa Inhibitor 72
3.4.4 Primary Prevention 73
3.4.5 Secondary Prevention 74
References 75
4. Orthostatic Hypotension
James J. Gugger and Megan J. Ehret
4.1 Epidemiology 81
4.1.1 Prevalence 81
4.1.2 Genetic Vulnerability 84
Contents vii
4.2 Pathobiology 84
4.3 Clinical and Laboratory Features 85
4.3.1 Autonomie Failure 86
4.3.2 Dehydration 86
4.3.3 Drug-Drug Interactions 87
4.3.4 Complications and Significant Sequelae 90
4.3.5 Risk Stratification for Death or Permanent
Disability 90
4.4 Prevention and Management 91
4.4.1 Antipsychotic Selection 91
4.4.2 Antipsychotic Reinitiation 91
4.4.3 Antipsychotic Dosing Frequency 91
4.4.4 Nonpharmacological Therapy 92
4.4.5 Volume Expansion 93
4.4.6 Pharmacological Therapy 93
4.4.7 Prevention 95
References 96
Part II
Hematological Complications of Treatment
With Antipsychotic Drugs
5. Severe Neutropenia and Agranulocytosis
John Lally and Robert J. Flanagan
5.1 Epidemiology 105
5.1.1 Drug-Induced Dyscrasias 110
5.1.2 Epidemiology of Clozapine-lnduced Neutropenia
and Agranulocytosis 111
5.2 Pathobiology 115
5.2.1 Mechanism of Clozapine-lnduced Neutropenia/
Agranulocytosis 117
5.3 Clinical and Laboratory Features 120
5.3.1 Clozapine-lnduced Neutropenia/Agranulocytosis 121
5.4 Prevention and Management 122
5.4.1 Clozapine and White Blood Count Monitoring 126
5.4.2 Neutropenic Risk in Clozapine-Treated Children
and Adolescents 135
5.4.3 Neutropenia/Agranulocytosis With Antipsychotics
Other Than Clozapi ne 13 6
5.4.4 Blood Dyscrasia Other Than Neutropenia Associated
With Antipsychotics 138
References 139
viii Contents
Part III
Antipsychotic-Related Pathology of the Digestive
System
6. Gastrointestinal Hypomotility and Dysphagia
Robert J. Flanagan and Kathlyn J. Ronaldson
6.1 Gastrointestinal Hypomotility 151
6.1.1 Introduction 151
6.1.2 Epidemiology 151
6.1.3 Pathobiology 160
6.1.4 Clinical and Laboratory Features 165
6.1.5 Imaging Studies 166
6.1.6 Differential Diagnosis 167
6.1.7 Complications and Significant Sequelae 167
6.1.8 Management 168
6.1.9 Prevention 170
6.1.10 Conclusion 172
6.2 Dysphagia and Sialorrhea 172
6.2.1 General Considerations 172
6.2.2 Pathobiology 172
6.2.3 Prevention and Management 173
Acknowledgment 174
References 174
7. Liver Failure
Katie F.M. Marwick
7.1 Definition 181
7.2 Search Strategy 181
7.3 Epidemiology 182
7.3.1 Acute Liver Failure 182
7.3.2 Asymptomatic Antipsychotic-lnduced Liver Injury
and Lesser Elevations in LFT 187
7.3.3 Genetic Vulnerability 190
7.4 Pathobiology 190
7.5 Clinical and Laboratory Features 191
7.5.1 Differential Diagnosis 192
7.5.2 Complications and Significant Sequelae 193
7.5.3 Risk Stratification for Death or Permanent Disability 193
7.6 Management 194
7.7 Prevention 195
7.8 Conclusion 195
References 196
Contents ix
8. Pancreatitis
Peter Manu, Matisyahu Shulman and Kathlyn J. Ronaldson
8.1 Epidemiology 199
8.2 Pathobiology 200
8.3 Clinical and Laboratory Features 201
8.4 Management 202
References 202
Part IV
Major Neurological and Neuromuscular Adverse
Effects of Antipsychotic Drugs
9. Seizures
Tilman Steinert and Walter Fröscher
9.1 Epidemiology 207
9.1.1 Seizures Occurring in Patients Receiving Therapeutic
Dosages of Antipsychotic Drugs 207
9.1.2 Seizures After Intoxications With Antipsychotic
Drugs 210
9.1.3 Genetic Vulnerability 210
9.2 Pathobiology 211
9.3 Clinical and Laboratory Features 212
9.3.1 Diagnostic Relevance of the EEG 212
9.3.2 Differential Diagnosis 214
9.3.3 Complications and Significant Sequelae 215
9.3.4 Risk Stratification for Death or Permanent
Disability 216
9.4 Prevention and Management 217
Acknowledgment 218
References 218
10. Neuroleptic Malignant Syndrome
Julie Langan Martin and Daniel J. Martin
10.1 Epidemiology 223
10.1.1 Genetic Vulnerability 224
10.1.2 Risk Factors 224
10.2 Pathobiology 226
10.2.1 Dopamine Receptor Blockade Hypothesis 226
10.2.2 Sympathoadrenal Hyperactivity 227
10.2.3 Musculoskeletal Fiber Toxicity Hypothesis 228
10.2.4 Neuroimmunological Hypothesis 228
x Contents
10.3 Clinical and Laboratory Features 228
10.3.1 Differential Diagnosis 230
10.3.2 Complications and Significant Sequelae 233
10.3.3 Risk of Recurrence 234
10.3.4 Risk Stratification for Death or Permanent Disability 234
10.4 Prevention and Management 234
References 236
11. Heat Stroke and Rhabdomyolysis
Kathlyn ]. Ronaldson
11.1 Heatstroke 241
11.1.1 Definition 241
11.1.2 Epidemiology 241
11.1.3 Pathobiology 243
11.1.4 Clinical and Laboratory Features 244
11.1.5 Differential Diagnosis 244
11.1.6 Complications and Significant Sequelae 244
11.1.7 Risk Stratification for Death or Permanent Disability 245
11.1.8 Management 245
11.1.9 Prevention 245
11.2 Rhabdomyolysis 246
11.2.1 Definition 246
11.2.2 Epidemiology 246
11.2.3 Pathobiology 247
11.2.4 Clinical and Laboratory Features 247
11.2.5 Differential Diagnosis 247
11.2.6 Complications and Significant Sequelae 248
11.2.7 Management 248
11.2.8 Conclusion 248
References 249
Part V
Metabolic Complications of Antipsychotic
Drug Treatment
12. Type 2 Diabetes Mellitus
Davy Vancampfort, Richard I.G. Holt, Brendort Stubbs,
Marc De Hert, Katherine Samaras and Alex /. Mitchell
12.1 Epidemiology 255
12.1.1 The Increased Risk of T2DM in People With
Severe Mental Illness 256
12.2 Pathobiology 259
12.3 Clinical and Laboratory Features 261
12.3.1 Categories of Increased Risk for Diabetes
(Prediabetes) 262
Contents xi
12.4 Prevention and Management 265
12.4.1 Screening for T2DM in People Taking Antipsychotics 265
12.4.2 Screening in People With Normal Baseline Tests 267
12.4.3 Screening in People With Risk Factors 267
12.4.4 Lifestyle Modification 267
12.4.5 Pharmacological Interventions 269
12.5 Conclusion 271
References 272
Part VI
Other Life-Threatening Effects of Antipsychotic Drugs
13. Interstitial Nephritis and Interstitial Lung Disease
Kathlyn J. Ronaldson
13.1 Interstitial Nephritis 281
13.1.1 Definition 281
13.1.2 Epidemiology 281
13.1.3 Pathobiology 283
13.1.4 Clinical and Laboratory Features 287
13.1.5 Differential Diagnosis 287
13.1.6 Management 287
13.1.7 Prevention 288
13.2 Interstitial Lung Disease 288
13.2.1 Definition 288
13.2.2 Epidemiology 289
13.2.3 Conclusion 291
References 291
Part VII
Clinical and Forensic Challenges in the Use
of Antipsychotic Drugs
14. The Benefits of Antipsychotic Drugs: Symptom
Control and Improved Quality of Life
Jian-Ping Zhang
14.1 Therapeutic Objectives in Schizophrenia 295
14.2 Pharmacology of Antipsychotic Drugs 296
14.3 Symptom Reduction in Schizophrenia 298
14.4 Relapse Prevention and Antipsychotic Maintenance
Treatment 300
14.5 Improving Quality of Life in Patients With Schizophrenia 302
14.6 Antipsychotic Drugs in Treating Other Psychiatric Disorders 303
References 306
xii Contents
15. Antipsychotic-Related Mortality: Risk and Strategy
for Improved Clinical Management
Dan Cohen
15.1 Reduced Life-expectancy with Severe Mental Illness (SMI) 311
15.1.1 Cardiovascular Disease Mortality 312
15.1.2 Sudden Cardiac Death 313
15.1.3 QTc-Prolongation 313
15.1.4 Brugada Syndrome 314
15.2 Suicide Reduced with Clozapine 315
15.3 An Obstacle to Clozapine Prescribing: Agranulocytosis 316
15.4 Diabetic Ketoacidosis: Poor Outcomes With Severe Mental
Illness (SMI) 318
15.5 Strategy for Improved Outcomes 321
15.5.1 Poor Care of Somatic Illness in Severe Mental
Illness (SMI) 321
15.5.2 Assertive Care for Mental Illness 322
15.5.3 Difficulties for Medical Practitioners 323
15.5.4 Assertive Care for Somatic Illness 325
15.5.5 Conclusion: Increase Clozapine Prescribing 327
References 327
Further Reading 332
16. Forensic Investigation of Antipsychotic-Related Deaths
Robert J. Flanagan and Peter Manu
16.1 Introduction 333
16.2 Clinical and Pathological Correlations 334
16.3 Toxicological Assessments 335
16.3.1 Postmortem Toxicology 336
16.3.2 Accuracy of a Diagnosis of Poisoning 339
16.3.3 Postmortem Biochemistry 341
16.4 System-Specific Forensic Considerations 342
16.4.1 Antipsychotics and Sudden Unexpected Death 342
16.4.2 Diabetes-Related Deaths 344
16.4.3 Seizure-Related Deaths 344
16.4.4 Other Potential Causes of Unexpected Death 344
16.5 Conclusions 346
References 346
Guide to the Interpretation of the Results of Some Chemical
Pathology Tests
Index
351
353
|
| any_adam_object | 1 |
| author | Manu, Peter |
| author_facet | Manu, Peter |
| author_role | aut |
| author_sort | Manu, Peter |
| author_variant | p m pm |
| building | Verbundindex |
| bvnumber | BV043895638 |
| collection | ZDB-30-PQE ZDB-33-ESD ZDB-33-EBS |
| ctrlnum | (ZDB-30-PQE)EBC4648365 (ZDB-89-EBL)EBL4648365 (ZDB-38-EBR)ebr11249443 (OCoLC)957318289 (DE-599)BVBBV043895638 |
| dewey-full | 615.7882 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7882 |
| dewey-search | 615.7882 |
| dewey-sort | 3615.7882 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01792nmm a2200421zc 4500</leader><controlfield tag="001">BV043895638</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">161123s2016 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780128033906</subfield><subfield code="9">978-0-12-803390-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780128033760</subfield><subfield code="c">Print</subfield><subfield code="9">978-0-12-803376-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PQE)EBC4648365</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL4648365</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-38-EBR)ebr11249443</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)957318289</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043895638</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield></datafield><datafield tag="082" ind1="1" ind2=" "><subfield code="a">615.7882</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Manu, Peter</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Life-Threatening Effects of Antipsychotic Drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Saint Louis</subfield><subfield code="b">Elsevier Science</subfield><subfield code="c">2016</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (396 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Flanagan, Robert J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ronaldson, Kathlyn J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Manu, Peter</subfield><subfield code="t">Life-Threatening Effects of Antipsychotic Drugs</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029305019&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PQE</subfield><subfield code="a">ZDB-33-ESD</subfield><subfield code="a">ZDB-33-EBS</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029305019</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.sciencedirect.com/science/book/9780128033760</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-33-ESD</subfield><subfield code="q">FAW_PDA_ESD</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.sciencedirect.com/science/book/9780128033760</subfield><subfield code="l">FLA01</subfield><subfield code="p">ZDB-33-ESD</subfield><subfield code="q">FLA_PDA_ESD</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043895638 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:37:52Z |
| institution | BVB |
| isbn | 9780128033906 9780128033760 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029305019 |
| oclc_num | 957318289 |
| open_access_boolean | |
| owner | DE-1046 |
| owner_facet | DE-1046 |
| physical | 1 online resource (396 pages) |
| psigel | ZDB-30-PQE ZDB-33-ESD ZDB-33-EBS ZDB-33-ESD FAW_PDA_ESD ZDB-33-ESD FLA_PDA_ESD |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Elsevier Science |
| record_format | marc |
| spelling | Manu, Peter Verfasser aut Life-Threatening Effects of Antipsychotic Drugs Saint Louis Elsevier Science 2016 © 2016 1 online resource (396 pages) txt rdacontent c rdamedia cr rdacarrier Description based on publisher supplied metadata and other sources Flanagan, Robert J. Sonstige oth Ronaldson, Kathlyn J. Sonstige oth Erscheint auch als Druck-Ausgabe Manu, Peter Life-Threatening Effects of Antipsychotic Drugs HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029305019&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Manu, Peter Life-Threatening Effects of Antipsychotic Drugs |
| title | Life-Threatening Effects of Antipsychotic Drugs |
| title_auth | Life-Threatening Effects of Antipsychotic Drugs |
| title_exact_search | Life-Threatening Effects of Antipsychotic Drugs |
| title_full | Life-Threatening Effects of Antipsychotic Drugs |
| title_fullStr | Life-Threatening Effects of Antipsychotic Drugs |
| title_full_unstemmed | Life-Threatening Effects of Antipsychotic Drugs |
| title_short | Life-Threatening Effects of Antipsychotic Drugs |
| title_sort | life threatening effects of antipsychotic drugs |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029305019&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT manupeter lifethreateningeffectsofantipsychoticdrugs AT flanaganrobertj lifethreateningeffectsofantipsychoticdrugs AT ronaldsonkathlynj lifethreateningeffectsofantipsychoticdrugs |